Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Gab3 is required for IL-2- and IL-15-induced NK cell expansion and limits trophoblast invasion during pregnancy.

Sliz A, Locker KCS, Lampe K, Godarova A, Plas DR, Janssen EM, Jones H, Herr AB, Hoebe K.

Sci Immunol. 2019 Aug 2;4(38). pii: eaav3866. doi: 10.1126/sciimmunol.aav3866.

PMID:
31375526
2.

R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling.

Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C, Yu M, Skibbe J, Dai Q, Zou D, Wu T, Yu K, Weng H, Huang H, Ferchen K, Qin X, Zhang B, Qi J, Sasaki AT, Plas DR, Bradner JE, Wei M, Marcucci G, Jiang X, Mulloy JC, Jin J, He C, Chen J.

Cell. 2018 Jan 11;172(1-2):90-105.e23. doi: 10.1016/j.cell.2017.11.031. Epub 2017 Dec 14.

3.

ERRα regulates the growth of triple-negative breast cancer cells via S6K1-dependent mechanism.

Berman AY, Manna S, Schwartz NS, Katz YE, Sun Y, Behrmann CA, Yu JJ, Plas DR, Alayev A, Holz MK.

Signal Transduct Target Ther. 2017;2. pii: e17035. doi: 10.1038/sigtrans.2017.35. Epub 2017 Aug 25.

4.

mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment.

Orr-Asman MA, Chu Z, Jiang M, Worley M, LaSance K, Koch SE, Carreira VS, Dahche HM, Plas DR, Komurov K, Qi X, Mercer CA, Anthony LB, Rubinstein J, Thomas HE.

Mol Cancer Ther. 2017 Nov;16(11):2432-2441. doi: 10.1158/1535-7163.MCT-17-0058. Epub 2017 Sep 1.

5.

Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.

Yoon SO, Shin S, Karreth FA, Buel GR, Jedrychowski MP, Plas DR, Dedhar S, Gygi SP, Roux PP, Dephoure N, Blenis J.

Mol Cell. 2017 Aug 3;67(3):512-527.e4. doi: 10.1016/j.molcel.2017.06.033. Epub 2017 Jul 27.

6.

Tuberin Regulates Prostaglandin Receptor-Mediated Viability, via Rheb, in mTORC1-Hyperactive Cells.

Li C, Liu X, Liu Y, Zhang E, Medepalli K, Masuda K, Li N, Wikenheiser-Brokamp KA, Osterburg A, Borchers MT, Kopras EJ, Plas DR, Sun J, Franz DN, Capal JK, Mays M, Sun Y, Kwiatkowski DJ, Alayev A, Holz MK, Krueger DA, Siroky BJ, Yu JJ.

Mol Cancer Res. 2017 Oct;15(10):1318-1330. doi: 10.1158/1541-7786.MCR-17-0077. Epub 2017 Jul 14.

7.

Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia.

Liu H, Feng X, Ennis KN, Behrmann CA, Sarma P, Jiang TT, Kofuji S, Niu L, Stratton Y, Thomas HE, Yoon SO, Sasaki AT, Plas DR.

Cell Rep. 2017 Feb 28;18(9):2088-2095. doi: 10.1016/j.celrep.2017.02.022.

8.

S6K1 regulates hematopoietic stem cell self-renewal and leukemia maintenance.

Ghosh J, Kobayashi M, Ramdas B, Chatterjee A, Ma P, Mali RS, Carlesso N, Liu Y, Plas DR, Chan RJ, Kapur R.

J Clin Invest. 2016 Jul 1;126(7):2621-5. doi: 10.1172/JCI84565. Epub 2016 Jun 13.

9.

Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.

Vallabhapurapu SD, Noothi SK, Pullum DA, Lawrie CH, Pallapati R, Potluri V, Kuntzen C, Khan S, Plas DR, Orlowski RZ, Chesi M, Kuehl WM, Bergsagel PL, Karin M, Vallabhapurapu S.

Nat Commun. 2015 Oct 12;6:8428. doi: 10.1038/ncomms9428.

PMID:
26455434
10.

ERK2 Mediates Metabolic Stress Response to Regulate Cell Fate.

Shin S, Buel GR, Wolgamott L, Plas DR, Asara JM, Blenis J, Yoon SO.

Mol Cell. 2015 Aug 6;59(3):382-98. doi: 10.1016/j.molcel.2015.06.020. Epub 2015 Jul 16.

11.

TRPM3 and miR-204 establish a regulatory circuit that controls oncogenic autophagy in clear cell renal cell carcinoma.

Hall DP, Cost NG, Hegde S, Kellner E, Mikhaylova O, Stratton Y, Ehmer B, Abplanalp WA, Pandey R, Biesiada J, Harteneck C, Plas DR, Meller J, Czyzyk-Krzeska MF.

Cancer Cell. 2014 Nov 10;26(5):738-53. doi: 10.1016/j.ccell.2014.09.015. Epub 2014 Nov 10.

12.

IL-15 Fosters Age-Driven Regulatory T Cell Accrual in the Face of Declining IL-2 Levels.

Raynor J, Sholl A, Plas DR, Bouillet P, Chougnet CA, Hildeman DA.

Front Immunol. 2013 Jun 24;4:161. doi: 10.3389/fimmu.2013.00161. eCollection 2013.

13.

Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma.

Unruh D, Turner K, Srinivasan R, Kocatürk B, Qi X, Chu Z, Aronow BJ, Plas DR, Gallo CA, Kalthoff H, Kirchhofer D, Ruf W, Ahmad SA, Lucas FV, Versteeg HH, Bogdanov VY.

Int J Cancer. 2014 Jan 1;134(1):9-20. doi: 10.1002/ijc.28327. Epub 2013 Jul 27.

14.

Control of nutrient stress-induced metabolic reprogramming by PKCζ in tumorigenesis.

Ma L, Tao Y, Duran A, Llado V, Galvez A, Barger JF, Castilla EA, Chen J, Yajima T, Porollo A, Medvedovic M, Brill LM, Plas DR, Riedl SJ, Leitges M, Diaz-Meco MT, Richardson AD, Moscat J.

Cell. 2013 Jan 31;152(3):599-611. doi: 10.1016/j.cell.2012.12.028.

15.

Not all autophagy is equal.

Czyzyk-Krzeska MF, Meller J, Plas DR.

Autophagy. 2012 Jul 1;8(7):1155-6. doi: 10.4161/auto.20650. Epub 2012 May 31.

16.

VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma.

Mikhaylova O, Stratton Y, Hall D, Kellner E, Ehmer B, Drew AF, Gallo CA, Plas DR, Biesiada J, Meller J, Czyzyk-Krzeska MF.

Cancer Cell. 2012 Apr 17;21(4):532-46. doi: 10.1016/j.ccr.2012.02.019.

17.

S6K1 determines the metabolic requirements for BCR-ABL survival.

Barger JF, Gallo CA, Tandon P, Liu H, Sullivan A, Grimes HL, Plas DR.

Oncogene. 2013 Jan 24;32(4):453-61. doi: 10.1038/onc.2012.70. Epub 2012 Mar 5.

18.

Loss of immunological tolerance in Gimap5-deficient mice is associated with loss of Foxo in CD4+ T cells.

Aksoylar HI, Lampe K, Barnes MJ, Plas DR, Hoebe K.

J Immunol. 2012 Jan 1;188(1):146-54. doi: 10.4049/jimmunol.1101206. Epub 2011 Nov 21.

19.

IKKβ and NF-κB transcription govern lymphoma cell survival through AKT-induced plasma membrane trafficking of GLUT1.

Sommermann TG, O'Neill K, Plas DR, Cahir-McFarland E.

Cancer Res. 2011 Dec 1;71(23):7291-300. doi: 10.1158/0008-5472.CAN-11-1715. Epub 2011 Oct 10.

20.

Interleukin-6 receptor enhances early colonization of the murine omentum by upregulation of a mannose family receptor, LY75, in ovarian tumor cells.

Giridhar PV, Funk HM, Gallo CA, Porollo A, Mercer CA, Plas DR, Drew AF.

Clin Exp Metastasis. 2011 Dec;28(8):887-97. doi: 10.1007/s10585-011-9420-x. Epub 2011 Sep 2.

PMID:
21887537
21.

Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition.

Coloff JL, Macintyre AN, Nichols AG, Liu T, Gallo CA, Plas DR, Rathmell JC.

Cancer Res. 2011 Aug 1;71(15):5204-13. doi: 10.1158/0008-5472.CAN-10-4531. Epub 2011 Jun 13.

22.

Requirement for ribosomal protein S6 kinase 1 to mediate glycolysis and apoptosis resistance induced by Pten deficiency.

Tandon P, Gallo CA, Khatri S, Barger JF, Yepiskoposyan H, Plas DR.

Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2361-5. doi: 10.1073/pnas.1013629108. Epub 2011 Jan 24.

23.

A major role for Bim in regulatory T cell homeostasis.

Chougnet CA, Tripathi P, Lages CS, Raynor J, Sholl A, Fink P, Plas DR, Hildeman DA.

J Immunol. 2011 Jan 1;186(1):156-63. doi: 10.4049/jimmunol.1001505. Epub 2010 Nov 22.

24.

Identification of Akt-selective cytotoxic compounds that enhance cytotoxic responses to rapamycin.

Barger JF, Gallo CA, Torni KA, Merk L, Seibel WL, Nelson S, Plas DR.

Cancer Biol Ther. 2010 Dec 15;10(12):1256-61. doi: 10.4161/cbt.10.12.13442. Epub 2010 Dec 15.

PMID:
20935504
25.

Balancing biosynthesis and bioenergetics: metabolic programs in oncogenesis.

Barger JF, Plas DR.

Endocr Relat Cancer. 2010 Sep 23;17(4):R287-304. doi: 10.1677/ERC-10-0106. Print 2010 Dec. Review.

PMID:
20699334
26.

FOXO3a regulates glycolysis via transcriptional control of tumor suppressor TSC1.

Khatri S, Yepiskoposyan H, Gallo CA, Tandon P, Plas DR.

J Biol Chem. 2010 May 21;285(21):15960-5. doi: 10.1074/jbc.M110.121871. Epub 2010 Apr 6.

27.

Targeting bioenergetics to enhance cancer chemotherapy: mitochondria SLP into apoptosis.

Khatri S, Plas DR.

Cancer Biol Ther. 2009 Sep;8(17):1659-61. Epub 2009 Sep 7. No abstract available.

28.

Tubers and tumors: rapamycin therapy for benign and malignant tumors.

Plas DR, Thomas G.

Curr Opin Cell Biol. 2009 Apr;21(2):230-6. doi: 10.1016/j.ceb.2008.12.013. Epub 2009 Feb 23. Review.

PMID:
19237273
29.

Akt-dependent transformation: there is more to growth than just surviving.

Plas DR, Thompson CB.

Oncogene. 2005 Nov 14;24(50):7435-42. Review.

PMID:
16288290
30.

AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.

Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB.

Mol Cell. 2005 Apr 29;18(3):283-93.

31.

Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand.

Bauer DE, Harris MH, Plas DR, Lum JJ, Hammerman PS, Rathmell JC, Riley JL, Thompson CB.

FASEB J. 2004 Aug;18(11):1303-5. Epub 2004 Jun 4.

32.

Akt stimulates aerobic glycolysis in cancer cells.

Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB.

Cancer Res. 2004 Jun 1;64(11):3892-9.

33.

Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis.

Arsham AM, Plas DR, Thompson CB, Simon MC.

Cancer Res. 2004 May 15;64(10):3500-7.

34.

Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival.

Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB.

Mol Cell Biol. 2003 Oct;23(20):7315-28.

35.

Bcl-x(L) and Akt cooperate to promote leukemogenesis in vivo.

Karnauskas R, Niu Q, Talapatra S, Plas DR, Greene ME, Crispino JD, Rudin CM.

Oncogene. 2003 Feb 6;22(5):688-98.

PMID:
12569361
36.

Akt activation promotes degradation of tuberin and FOXO3a via the proteasome.

Plas DR, Thompson CB.

J Biol Chem. 2003 Apr 4;278(14):12361-6. Epub 2003 Jan 6.

37.

The CD28 signaling pathway regulates glucose metabolism.

Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, Elstrom RL, June CH, Thompson CB.

Immunity. 2002 Jun;16(6):769-77.

38.

Homeostatic control of lymphocyte survival: potential origins and implications.

Plas DR, Rathmell JC, Thompson CB.

Nat Immunol. 2002 Jun;3(6):515-21. Review.

PMID:
12032565
39.
40.

Cell metabolism in the regulation of programmed cell death.

Plas DR, Thompson CB.

Trends Endocrinol Metab. 2002 Mar;13(2):75-8. Review.

PMID:
11854022
41.

Growth factors can influence cell growth and survival through effects on glucose metabolism.

Vander Heiden MG, Plas DR, Rathmell JC, Fox CJ, Harris MH, Thompson CB.

Mol Cell Biol. 2001 Sep;21(17):5899-912.

42.

Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology.

Plas DR, Talapatra S, Edinger AL, Rathmell JC, Thompson CB.

J Biol Chem. 2001 Apr 13;276(15):12041-8. Epub 2001 Jan 12.

43.

Cutting edge: the tyrosine phosphatase SHP-1 regulates thymocyte positive selection.

Plas DR, Williams CB, Kersh GJ, White LS, White JM, Paust S, Ulyanova T, Allen PM, Thomas ML.

J Immunol. 1999 May 15;162(10):5680-4.

44.
45.
46.

Negative regulation of antigen receptor signaling in lymphocytes.

Plas DR, Thomas ML.

J Mol Med (Berl). 1998 Jul;76(8):589-95. Review.

PMID:
9694436
47.

Affinity maturation without germinal centres in lymphotoxin-alpha-deficient mice.

Matsumoto M, Lo SF, Carruthers CJ, Min J, Mariathasan S, Huang G, Plas DR, Martin SM, Geha RS, Nahm MH, Chaplin DD.

Nature. 1996 Aug 1;382(6590):462-6.

PMID:
8684487
48.

Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling.

Plas DR, Johnson R, Pingel JT, Matthews RJ, Dalton M, Roy G, Chan AC, Thomas ML.

Science. 1996 May 24;272(5265):1173-6.

PMID:
8638162
49.

Riboflavin uptake in microvillous and basal membrane vesicles isolated from full-term human placentas.

Moe AJ, Plas DR, Powell KA, Smith CH.

Placenta. 1994 Feb-Mar;15(2):137-46.

PMID:
8008729

Supplemental Content

Support Center